Chimerix
Antiviral Drugs for DNA Viruses.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $935m Valuation: $935m | Acquisition | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 61 % | 73 % | (57 %) | (63 %) | 1609 % | (99 %) | (35 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (980 %) | 113 % | (829 %) | (385 %) | (858 %) | (28696 %) | (45506 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (963 %) | (899 %) | (810 %) | (8754 %) | 509 % | (25338 %) | (41692 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 766 % | 338 % | 674 % | 3730 % | 212 % | 21231 % | 35176 % |
Source: Company filings or news article
Related Content
Chimerix, Inc. is a biopharmaceutical company focused on developing innovative antiviral therapies to address unmet medical needs in infectious diseases and oncology. The company primarily serves healthcare providers, hospitals, and patients who require advanced treatment options for life-threatening conditions. Operating in the biopharmaceutical market, Chimerix employs a research-driven business model, investing heavily in clinical trials and regulatory approvals to bring its products to market. Revenue is generated through the sale of approved therapies and potential partnerships or licensing agreements with other pharmaceutical companies. Key products include brincidofovir, an antiviral medication aimed at treating various viral infections. The company is also exploring treatments for acute myeloid leukemia and other cancers. Chimerix's strategic focus on high-need areas positions it as a critical player in the healthcare industry, aiming to improve patient outcomes through cutting-edge science.
Keywords: antiviral therapies, infectious diseases, oncology, biopharmaceutical, brincidofovir, clinical trials, healthcare providers, hospitals, acute myeloid leukemia, patient outcomes.